CeNeS Pharmaceuticals PLC (CEN.L): Clinical Trial Results; Positive Preliminary Results With M6G From Phase III Trial In Post-Operative Pain
10/19/2005 5:11:29 PM
CeNeS Pharmaceuticals plc (LSE: CEN) ("CeNeS" or "the Company") today announced positive preliminary results in a Phase III clinical trial to assess the efficacy of M6G (morphine-6-glucuronide) as an analgesic in patients suffering from post-operative pain (p less than 0.05). The Phase III study also confirmed the effective dose of M6G and supported the findings of earlier volunteer and Phase II studies that M6G treated patients suffer less nausea and vomiting when compared to patients receiving morphine.
comments powered by